[1]
F. M. Quaglia, “Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation”, Mediterr J Hematol Infect Dis, vol. 11, no. 1, p. e2019057, Aug. 2019.